EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis

Rasmus Hansen Henninger iD, Wietse M Schouten, Byron Arana iD, Jean-Yves Gillon iD, Charles E Mowbray iD, Jadel Müller Kratz, Katrien Van Bocxlaer, Thomas P C Dorlo iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Rasmus Hansen Henninger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Leishmaniasis, Cutaneous, Models, Biological, Antiprotozoal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous leishmaniasis is a neglected tropical disease with only one oral treatment option. DNDI‐6148 is an orally bioavailable compound with potent antiparasitic activity in preclinical studies. Establishing skin target‐site pharmacokinetic/pharmacodynamic (PK/PD) relationships is essential to enable its clinical development. The objective was to characterize the target‐site PK and PD of DNDI‐6148 in a murine L. major model and to predict a human efficacious dose. A nonlinear mixed‐effects PK/PD model was developed using data from L. major ‐infected BALB/c mice orally administered DNDI‐6148 (6.25–50 mg/kg, bid). The murine PD components and skin distribution characteristics were used jointly with allometrically scaled human PK parameters to predict a clinically efficacious dose. DNDI‐6148 PK in mice was described by a one‐compartment model with dose‐dependent bioavailability, saturable clearance, and a skin‐to‐plasma ratio of 0.56 [95% CI, 0.49–0.68] for both infected and non‐infected skin. Parasite clearance at the infection site followed a sigmoidal E max relationship, driven by free skin concentrations ( fEC5 0 : 165 μg/L [95% CI, 125–236]). Human PK parameters for clearance, volume of distribution, and absorption rate were predicted to 3.44 L/h, 79.5 L and 0.360 h −1 , respectively. DNDI‐6148 doses of 4.0 and 6.0 mg/kg once daily for 14 days were predicted to achieve 95% and 99% parasite reduction from baseline, respectively, in > 90% of simulated patients. This translational PK/PD modeling framework based on a murine infection model of cutaneous leishmaniasis effectively informs human dose selection by accounting for both PK and PD at the skin target site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, CutaneousModels, BiologicalAntiprotozoal AgentsAnimalsHumansMiceMice, Inbred BALB CDose-Response Relationship, DrugFemaleDisease Models, AnimalAdministration, OralLeishmania majorSkinBiological AvailabilityTranslational Research, BiomedicalBenzoxazolesBoron CompoundsPyridines

Stichwörter der Autor:innen

infectious diseasemodel based drug developmenttranslational pharmacokinetics‐pharmacodynamicstropical diseases

Substanzen

Antiprotozoal AgentsDNDI-6148BenzoxazolesBoron CompoundsPyridines

Autor:innen und Institutionen

  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
  • Drugs for Neglected Diseases Initiative Latin America, Rio de Janeiro, Brazil.
  • Skin Research Centre, Hull York Medical School, York Biomedical Research Institute, University of York, York, UK.

ORCID-Profile: Rasmus Hansen Henninger, Byron Arana, Jean-Yves Gillon, Charles E Mowbray, Thomas P C Dorlo

Zitieren

APA

Henninger, R. H., Schouten, W. M., Arana, B., Gillon, J. Y., Mowbray, C. E., Kratz, J. M., Van Bocxlaer, K., & Dorlo, T. P. C. (2026). Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis. Clinical and Translational Science. https://doi.org/10.1111/cts.70535

Vancouver

Henninger RH, Schouten WM, Arana B, Gillon JY, Mowbray CE, Kratz JM, et al. Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis. Clinical and Translational Science. 2026. doi:10.1111/cts.70535

BibTeX
@article{Henninger2026,
  author = {Henninger, Rasmus Hansen and Schouten, Wietse M and Arana, Byron and Gillon, Jean-Yves and Mowbray, Charles E and Kratz, Jadel Müller and Van Bocxlaer, Katrien and Dorlo, Thomas P C},
  title = {Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70535}
}
Kostenlos starten →